関連する実験動画
Updated: Feb 21, 2026

14:55
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
Published on: May 12, 2013
62.0K
キュッシング症候群の治療のためのオシロドロスタット:最新情報
Lukasz Dzialach1, Przemyslaw Witek1
1Department of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw, Warsaw, Poland.
Expert review of endocrinology & metabolism
|February 20, 2026
まとめ
オシロドロスタットは,クッシング症候群 (CS) のコルチゾルを効果的に低下させ,患者のアウトカムを改善します. このレビューは,その有効性,安全性,および実践的な管理をカバーし,この複雑な内分泌障害の治療におけるその価値を強調します.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 薬理学 薬理学とは
背景:
- クッシング症候群 (CS) は,複雑な内分泌の課題を提示し,長期的な管理が困難です.
- 11β-ヒドロキシラーゼ阻害剤であるオシロドロスタートは,新しい治療の機会を提供します.
研究 の 目的:
- CSにおけるオシロドロスタットの有効性および安全性に関する臨床および実世界のデータをレビューする.
- オシロドロスタットの使用に関する実用的なガイドラインを提供し,投与量および有害事象管理を含む.
主な方法:
- 現在の臨床的証拠のレビュー.
- 固有の高コルチゾーリズムにおけるオシロドロスタットに関する現実世界のデータの分析.
主要な成果:
- オシロドロスタートは,コルチゾールの有意な減少を示し,代謝,心血管,および心理的健康を改善します.
- それは,様々なCS形態と重症度において,よく耐えており,有効です.
結論:
- オシロドロスタートは,クッシング症候群の価値ある効果的な治療法です.
- 現実世界の証拠は,内生性高コルチゾル症の管理におけるその有用性を支持しています.
キーワード:
クッシング病はクッシング病です.キュッシング症候群 (Cushing syndrome) とは,クッシング症候群 (Cushing syndrome) とは,キュッシング症候群 (Cushing syndrome) とは,キュッシング症候群 (Cushing syndrome) とは,キュッシング症候群 (Cushing syndrome) とは,キュッシング症候群 (Cushing syndrome) とは,キュッシング症候群 (Cushing syndrome) とは,キュッシング症候群 (Cushing syndrome) とは,キュッシング症候群 (Cushing syndrome) とは,キュッシング症候群 (Cushing syndrome) とはハイパーコルチゾーリズム医療処置 医療処置 医療処置オシロドロスタット オシロドロスタット関連する概念動画
Drugs for Treatment of Constipation-Predominant IBS
926
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
926
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
546
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
546
Drug Dosing: Obese Patients
298
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
298
COPD: Management Using Bronchodilators and Corticosteroids
888
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
888
Drugs for Treatment of Diarrhea-Predominant IBS
767
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
767
Oral Hypoglycemic Agents: Sulfonylureas
1.3K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.3K
